1
|
Antier C, Jullien M, Tessoulin B, Loirat M, Peterlin P, Garnier A, Le Bourgeois A, Chevallier P, Guillaume T. Late Relapse after Allogeneic Stem Cell Transplantation in Patients Treated for Acute Myeloid Leukemia: Relapse Incidence, Characteristics, Role of Conditioning Regimen, and Outcome. Cancers (Basel) 2024; 16:1419. [PMID: 38611097 PMCID: PMC11011193 DOI: 10.3390/cancers16071419] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/13/2024] [Revised: 03/25/2024] [Accepted: 04/02/2024] [Indexed: 04/14/2024] Open
Abstract
Late relapse, beyond 2 years following alloHSCT for AML, is rare. Among the 376 patients allografted for AML in our center between 1990 and 2016, 142 (38%) relapsed. The majority (68%) of relapses occurred during the first year following transplantation. Beyond 2 years after alloHSCT, relapse was observed in 26 patients, representing 6.9% of the whole transplanted cohort and 18.3% of the relapsing patients. Cytogenetics at relapse was available in 21 patients and remained for 15 of them concordant to that at diagnosis. The majority (85.7%) of the patients were in CR prior to transplant. Thirteen patients had grade 1-2 acute GvHD, while 13 other patients had grade 3-4 acute GvHD. None of these patients subsequently developed chronic GvHD. In multivariate analyses, a predictive factor of the absence of relapse 2 years after transplantation was the development of extensive chronic GVHD. Salvage therapy achieved new CR in 77% of these patients. We conclude that late relapse can affect a significant minority of patients allografted for AML, and the intensity of the conditioning regimen does not seem to have an impact on these relapses. Moreover, we were able to show that those patients can receive effective salvage therapy.
Collapse
Affiliation(s)
| | | | | | | | | | | | | | | | - Thierry Guillaume
- Department of Hematology, Nantes University Hospital, Hôtel-Dieu, F-44903 Nantes, France; (C.A.); (M.J.); (B.T.); (M.L.); (P.P.); (A.G.); (A.L.B.); (P.C.)
| |
Collapse
|
2
|
Jullien M, Guillaume T, Le Bourgeois A, Peterlin P, Garnier A, Eveillard M, Le Bris Y, Bouzy S, Tessoulin B, Gastinne T, Dubruille V, Touzeau C, Mahé B, Blin N, Lok A, Vantyghem S, Sortais C, Antier C, Moreau P, Scotet E, Béné MC, Chevallier P. Phase I study of zoledronic acid combined with escalated doses of interleukine-2 for early in vivo generation of Vγ9Vδ2 T-cells after haploidentical stem cell transplant with posttransplant cyclophosphamide. Am J Hematol 2024; 99:350-359. [PMID: 38165016 DOI: 10.1002/ajh.27191] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/22/2023] [Revised: 11/22/2023] [Accepted: 11/30/2023] [Indexed: 01/03/2024]
Abstract
The presence of donor Vγ9Vδ2 T-cells after haploidentical hematopoietic stem cell transplant (h-HSCT) has been associated with improved disease-free survival. These cells kill tumor cells in a non-MHC restricted manner, do not induce graft-versus-host disease (GVHD), and can be generated by stimulation with zoledronic acid (ZA) in combination with interleukin-2 (IL-2). This monocentric phase I, open-label, dose-escalating study (ClinicalTrials.gov: NCT03862833) aimed at evaluating the safety and possibility to generate Vγ9Vδ2 T-cells early after h-HSCT. It applied a standard 3 + 3 protocol to determine the maximum tolerated dose (MTD) of increasing low-doses of IL-2 (5 days [d] per week, 4 weeks) in combination with a single dose of ZA, starting both the first Monday after d + 15 posttransplant. Vγ9Vδ2 T-cell monitoring was performed by multiparameter flow cytometry on blood samples and compared with a control cohort of h-HSCT recipients. Twenty-six patients were included between April 2019 and September 2022, 16 of whom being ultimately treated and seven being controls who received h-HSCT only. At the three dose levels tested, 1, 0, and 1 dose-limiting toxicities were observed. MTD was not reached. A significantly higher number of Vγ9Vδ2 T-cells was observed during IL-2 treatment compared with controls. In conclusion, early in vivo generation of Vγ9Vδ2 T-cells is feasible after h-HSCT by using a combination of ZA and repeated IL-2 infusions. This study paves the way to a future phase 2 study, with the hope to document lesser posttransplant relapse with this particular adaptive immunotherapy.
Collapse
Affiliation(s)
- Maxime Jullien
- Hematology Department, Nantes University Hospital, Nantes, France
- Nantes Université, Inserm UMR 1307, CNRS UMR 6075, Université d'Angers, CRCI2NA, Nantes, France
- LabEx IGO "Immunotherapy, Graft, Oncology", Nantes, France
| | - Thierry Guillaume
- Hematology Department, Nantes University Hospital, Nantes, France
- Nantes Université, Inserm UMR 1307, CNRS UMR 6075, Université d'Angers, CRCI2NA, Nantes, France
- LabEx IGO "Immunotherapy, Graft, Oncology", Nantes, France
| | | | - Pierre Peterlin
- Hematology Department, Nantes University Hospital, Nantes, France
| | - Alice Garnier
- Hematology Department, Nantes University Hospital, Nantes, France
| | - Marion Eveillard
- Nantes Université, Inserm UMR 1307, CNRS UMR 6075, Université d'Angers, CRCI2NA, Nantes, France
- LabEx IGO "Immunotherapy, Graft, Oncology", Nantes, France
- Hematology Biology, Nantes University Hospital, Nantes, France
| | - Yannick Le Bris
- Nantes Université, Inserm UMR 1307, CNRS UMR 6075, Université d'Angers, CRCI2NA, Nantes, France
- LabEx IGO "Immunotherapy, Graft, Oncology", Nantes, France
- Hematology Biology, Nantes University Hospital, Nantes, France
| | - Simon Bouzy
- Hematology Biology, Nantes University Hospital, Nantes, France
| | - Benoît Tessoulin
- Hematology Department, Nantes University Hospital, Nantes, France
| | - Thomas Gastinne
- Hematology Department, Nantes University Hospital, Nantes, France
| | | | - Cyrille Touzeau
- Hematology Department, Nantes University Hospital, Nantes, France
| | - Béatrice Mahé
- Hematology Department, Nantes University Hospital, Nantes, France
| | - Nicolas Blin
- Hematology Department, Nantes University Hospital, Nantes, France
| | - Anne Lok
- Hematology Department, Nantes University Hospital, Nantes, France
| | - Sophie Vantyghem
- Hematology Department, Nantes University Hospital, Nantes, France
| | - Clara Sortais
- Hematology Department, Nantes University Hospital, Nantes, France
| | - Chloé Antier
- Hematology Department, Nantes University Hospital, Nantes, France
| | - Philippe Moreau
- Hematology Department, Nantes University Hospital, Nantes, France
| | - Emmanuel Scotet
- Nantes Université, Inserm UMR 1307, CNRS UMR 6075, Université d'Angers, CRCI2NA, Nantes, France
- LabEx IGO "Immunotherapy, Graft, Oncology", Nantes, France
| | - Marie C Béné
- Nantes Université, Inserm UMR 1307, CNRS UMR 6075, Université d'Angers, CRCI2NA, Nantes, France
- LabEx IGO "Immunotherapy, Graft, Oncology", Nantes, France
- Hematology Biology, Nantes University Hospital, Nantes, France
| | - Patrice Chevallier
- Hematology Department, Nantes University Hospital, Nantes, France
- Nantes Université, Inserm UMR 1307, CNRS UMR 6075, Université d'Angers, CRCI2NA, Nantes, France
- LabEx IGO "Immunotherapy, Graft, Oncology", Nantes, France
| |
Collapse
|
3
|
Stathis A, Pirosa MC, Orsucci L, Feugier P, Tani M, Ghesquières H, Musuraca G, Rossi FG, Merli F, Guièze R, Gyan E, Gini G, Marino D, Gressin R, Morschhauser F, Cavallo F, Palombi F, Conconi A, Tessoulin B, Tilly H, Zanni M, Cabras MG, Capochiani E, Califano C, Celli M, Pulsoni A, Angrilli F, Occhini U, Casasnovas RO, Cartron G, Devizzi L, Haioun C, Liberati AM, Houot R, Merli M, Pietrantuono G, Re F, Spina M, Landi F, Cavalli F, Bertoni F, Rossi D, Ielmini N, Borgo E, Luminari S, Zucca E, Thieblemont C. IELSG38: phase II trial of front-line chlorambucil plus subcutaneous rituximab induction and maintenance in mucosa-associated lymphoid tissue lymphoma. Haematologica 2024. [PMID: 38385243 DOI: 10.3324/haematol.2023.283918] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/14/2023] [Indexed: 02/23/2024] Open
Abstract
The IELSG38 trial was conducted to investigate the effects of subcutaneous (SC) rituximab on the complete remission (CR) rate and the benefits of SC maintenance in patients with extranodal marginal zone lymphoma (MZL) who received frontline treatment with chlorambucil plus rituximab. Study treatment comprised an induction phase with chlorambucil 6 mg/m2/day orally on weeks 1-6, 9-10, 13-14, 17-18, and 21-22, and rituximab 375 mg/m2 intravenously on day 1 of weeks 1-4, and 1400 mg SC on weeks 9, 13, 17, and 21. Then, a maintenance phase followed with rituximab administered at 1400 mg SC every two months for two years. Of the 112 patients enrolled, 109 were evaluated for efficacy. The CR rates increased from 52% at the end of the induction phase to 70% upon completion of the maintenance phase. With a median follow-up of 5.8 years, the 5-year event-free, progression-free, and overall survival rates were 87% (95% CI, 78-92), 84% (95% CI, 75-89), and 93% (95% CI, 86-96), respectively. The most common grade ≥3 toxicities were neutropenia (33%) and lymphocytopenia (16%). Six patients experienced treatment-related serious adverse events, including fever of unknown origin, sepsis, pneumonia, respiratory failure, severe cerebellar ataxia, and fatal acute myeloid leukemia. The trial showed that subcutaneous rituximab did not improve the complete remission rate at the conclusion of the induction phase, which was the main endpoint. Nevertheless, SC maintenance might have facilitated long-term disease control, potentially contributing to enhanced event-free and progression-free survival.
Collapse
Affiliation(s)
- Anastasios Stathis
- Oncology Institute of Southern Switzerland, EOC, Bellinzona, Switzerland; Università della Svizzera Italiana, Faculty of Biomedical Sciences, Lugano.
| | - Maria Cristina Pirosa
- Oncology Institute of Southern Switzerland, EOC, Bellinzona, Switzerland; Institute of Oncology Research, Bellinzona
| | - Lorella Orsucci
- S.C. Ematologia, AOU Città della Salute e della Scienza di Torino, Turin
| | - Pierre Feugier
- Department of Clinical Hematology, Nancy University Hospital, INSERM 1256, Nancy
| | - Monica Tani
- U.O. Ematologia, Dipartimento Oncologia e Ematologia, Ospedale Santa Maria delle Croci, Ravenna
| | - Hervé Ghesquières
- Hematology Department, Hospices Civils de Lyon, CHU Lyon-Sud, Pierre-Bénite
| | - Gerardo Musuraca
- Hematology Unit, IRCCS Istituto Scientifico Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", Meldola
| | - Francesca Gaia Rossi
- Hematology-BMT Center, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, University of Milan, Milano
| | | | - Romain Guièze
- Service d'Hématologie Clinique et de Thérapie Cellulaire, CHU Estaing, Clermont- Ferrand
| | - Emmanuel Gyan
- Hématologie et thérapie cellulaire, CIC Inserm U1415, Centre Hospitalier Universitaire de Tours, Tours
| | - Guido Gini
- Hematology, Department of Clinical and Molecular Sciences, Marche Polytechnic University, Ancona
| | - Dario Marino
- Oncology 1 Unit, Istituto Oncologico Veneto IOV-IRCCS, Padova
| | - Remy Gressin
- Institute for Advanced Biosciences, INSERM U1209/CNRS UMR 5309/Grenoble Alpes University, Grenoble
| | | | - Federica Cavallo
- Division of Hematology, Department of Molecular Biotechnologies and Health Sciences, University of Torino/AOU Città della Salute e della Scienza di Torino, Turin
| | - Francesca Palombi
- Hematology and Stem Cell Transplant Unit, IRCCS. National Cancer Institute, Istituto Regina Elena, Rome Italy
| | | | - Benoît Tessoulin
- Hématologie Clinique, CHU de Nantes, INSERM CRCINA Nantes-Angers, NeXT Université de Nantes, Nantes
| | - Hervé Tilly
- Department of Hematology and U1245, Centre Henri Becquerel, Rouen
| | - Manuela Zanni
- Hematology Unit, Antonio e Biagio e Cesare Arrigo Hospital, Alessandria
| | | | - Enrico Capochiani
- Hematology Unit, Azienda USL Toscana NordOvest, Center for Translational Medicine, Livorno
| | | | | | - Alessandro Pulsoni
- Department of Translational and Precision Medicine, Sapienza University, Rome
| | - Francesco Angrilli
- Unità Operativa Semplice Dipartimentale Centro Diagnosi e Terapia Linfomi, Presidio Ospedaliero, Pescara
| | - Ubaldo Occhini
- Unità Operativa di Ematologia, Ospedale San Donato, AUSL Toscana Sud-Est, Arezzo
| | | | | | - Liliana Devizzi
- Hematology Unit, Fondazione IRCCS, Istituto Nazionale dei Tumori, Milan
| | - Corinne Haioun
- Lymphoid Malignancies Unit, Hôpital Henri Mondor, AP-HP, Créteil
| | - Anna Marina Liberati
- SC Oncoematologia, Azienda Ospedaliera Santa Maria, Università degli studi di Perugia, Terni
| | - Roch Houot
- Department of Clinical Hematology, University Hospital of Rennes, Rennes
| | - Michele Merli
- Division of Hematology, University Hospital Ospedale di Circolo e Fondazione Macchi ASST Sette Laghi, University of Insubria, Varese
| | - Giuseppe Pietrantuono
- Hematology Unit, Centro di Riferimento Oncologico della Basilicata IRCCS Rionero in Vulture
| | - Francesca Re
- Hematology and BMT Center, Azienda Ospedaliera Universitaria, Parma
| | - Michele Spina
- Division of Medical Oncology, Centro di Riferimento Oncologico IRCCS, Aviano
| | | | | | - Francesco Bertoni
- Oncology Institute of Southern Switzerland, EOC, Bellinzona, Switzerland; Università della Svizzera Italiana, Faculty of Biomedical Sciences, Lugano, Switzerland; Institute of Oncology Research, Bellinzona
| | - Davide Rossi
- Oncology Institute of Southern Switzerland, EOC, Bellinzona, Switzerland; Università della Svizzera Italiana, Faculty of Biomedical Sciences, Lugano, Switzerland; Institute of Oncology Research, Bellinzona
| | | | - Elena Borgo
- FIL, Fondazione Italiana Linfomi ONLUS, Alessandria
| | - Stefano Luminari
- AUSL-IRCCS of Reggio Emilia, Reggio Emilia, Italy; CHIMOMO Department, University of Modena and Reggio Emilia, Reggio Emilia
| | - Emanuele Zucca
- Oncology Institute of Southern Switzerland, EOC, Bellinzona, Switzerland; Università della Svizzera Italiana, Faculty of Biomedical Sciences, Lugano, Switzerland; Institute of Oncology Research, Bellinzona, Switzerland; Medical Oncology, University Hospital and University of Bern
| | - Catherine Thieblemont
- APHP - Service d'Hématologie-Oncologie, Hôpital Saint Louis, Université de Paris - Diderot, Paris
| |
Collapse
|
4
|
Lécuyer R, Issa N, Camou F, Lavergne RA, Gabriel F, Morio F, Canet E, Raffi F, Boutoille D, Cady A, Gousseff M, Crabol Y, Néel A, Tessoulin B, Gaborit B. Characteristics and Prognosis Factors of Pneumocystis jirovecii Pneumonia According to Underlying Disease: A Retrospective Multicenter Study. Chest 2024:S0012-3692(24)00022-9. [PMID: 38215935 DOI: 10.1016/j.chest.2024.01.015] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/11/2023] [Revised: 12/15/2023] [Accepted: 01/05/2024] [Indexed: 01/14/2024] Open
Abstract
BACKGROUND Pneumocystis jirovecii pneumonia (PcP) remains associated with high rates of mortality, and the impact of immunocompromising underlying disease on the clinical presentation, severity, and mortality of PcP has not been adequately evaluated. RESEARCH QUESTION Does the underlying disease and immunosuppression causing PcP impact the outcome and clinical presentation of the disease? STUDY DESIGN AND METHODS In this multicenter retrospective observational study, conducted from January 2011 to December 2021, all consecutive patients admitted with a proven or probable diagnosis of PcP according to the European Organisation for Research and Treatment of Cancer consensus definitions were included to assess the epidemiology and impact of underlying immunosuppressive diseases on overall and 90-day mortality. RESULTS Overall, 481 patients were included in the study; 180 (37.4%) were defined as proven PcP and 301 (62.6%) were defined as probable PcP. Patients with immune-mediated inflammatory diseases (IMIDs) or solid tumors had a statistically poorer prognosis than other patients with PcP at day 90. In multivariate analysis, among the HIV-negative population, solid tumor underlying disease (OR, 5.47; 95% CI, 2.16-14.1; P < .001), IMIDs (OR, 2.19; 95% CI, 1.05-4.60; P = .037), long-term corticosteroid exposure (OR, 2.07; 95% CI, 1.03-4.31; P = .045), cysts in sputum/BAL smears (OR, 1.92; 95% CI, 1.02-3.62; P = .043), and SOFA score at admission (OR, 1.58; 95% CI, 1.39-1.82; P < .001) were independently associated with 90-day mortality. Prior corticotherapy was the only immunosuppressant associated with 90-day mortality (OR, 1.67; 95% CI, 1.03-2.71; P = .035), especially for a prednisone daily dose ≥ 10 mg (OR, 1.80; 95% CI, 1.14-2.85; P = .010). INTERPRETATION Among patients who were HIV-negative, long-term corticosteroid prior to PcP diagnosis was independently associated with increased 90-day mortality, specifically in patients with IMIDs. These results highlight both the needs for PcP prophylaxis in patients with IMIDs and to early consider PcP curative treatment in severe pneumonia among patients with IMIDs.
Collapse
Affiliation(s)
- Romain Lécuyer
- Internal Medicine and Infectious Diseases, Centre Hospitalier Bretagne-Atlantique, Vannes, France; Nantes Université, CHU Nantes, Cibles et médicaments des infections et de l'immunité, IICiMed, UR1155, Nantes, France
| | - Nahéma Issa
- Intensive Care and Infectious Disease Unit, Groupe Saint-André, University Hospital, Bordeaux, France
| | - Fabrice Camou
- Intensive Care and Infectious Disease Unit, Groupe Saint-André, University Hospital, Bordeaux, France
| | - Rose-Anne Lavergne
- Nantes Université, CHU Nantes, Cibles et médicaments des infections et de l'immunité, IICiMed, UR1155, Nantes, France
| | - Frederic Gabriel
- Centre Hospitalier Universitaire de Bordeaux, Service de Parasitologie Mycologie, Bordeaux, France
| | - Florent Morio
- Nantes Université, CHU Nantes, Cibles et médicaments des infections et de l'immunité, IICiMed, UR1155, Nantes, France; Laboratoire de Parasitologie-Mycologie, Institut de Biologie, University Hospital, Nantes, France
| | - Emmanuel Canet
- Medical Intensive Care, University Hospital, Nantes, France
| | - François Raffi
- Department of Infectious Diseases, University Hospital of Nantes and Centre d'Investigation Clinique 1413, INSERM, Nantes, France
| | - David Boutoille
- Department of Infectious Diseases, University Hospital of Nantes and Centre d'Investigation Clinique 1413, INSERM, Nantes, France; Nantes Université, CHU Nantes, INSERM, Center for Research in Transplantation and Translational Immunology, UMR 1064, Nantes, France
| | - Anne Cady
- Department of Microbiology, Centre Hospitalier Bretagne-Atlantique, Vannes, France
| | - Marie Gousseff
- Internal Medicine and Infectious Diseases, Centre Hospitalier Bretagne-Atlantique, Vannes, France
| | - Yoann Crabol
- Internal Medicine and Infectious Diseases, Centre Hospitalier Bretagne-Atlantique, Vannes, France
| | - Antoine Néel
- CRTI UMR 1064, INSERM, Université de Nantes, Nantes, France; Department of Internal Medicine, University Hospital, Nantes, France
| | - Benoît Tessoulin
- INSERM, U1232, Hematology Department, Nantes University Hospital, CRCI(2)NA, Nantes University, Nantes, France
| | - Benjamin Gaborit
- Department of Infectious Diseases, University Hospital of Nantes and Centre d'Investigation Clinique 1413, INSERM, Nantes, France; Nantes Université, CHU Nantes, INSERM, Center for Research in Transplantation and Translational Immunology, UMR 1064, Nantes, France.
| |
Collapse
|
5
|
Piron B, Bastien M, Antier C, Dalla-Torre R, Jamet B, Gastinne T, Dubruille V, Moreau P, Martin J, Bénichou A, Touzeau C, Tessoulin B. Immune-related adverse events with bispecific T-cell engager therapy targeting B-cell maturation antigen. Haematologica 2024; 109:357-361. [PMID: 37470151 PMCID: PMC10772518 DOI: 10.3324/haematol.2023.282919] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/15/2023] [Accepted: 07/11/2023] [Indexed: 07/21/2023] Open
Abstract
Not available.
Collapse
Affiliation(s)
| | | | - Chloé Antier
- Department of hematology, University hospital, Nantes
| | | | - Bastien Jamet
- Department of nuclear medicine, University hospital, Nantes
| | | | | | - Philippe Moreau
- Department of hematology, University hospital, Nantes, France; Centre de Recherche en Cancérologie et Immunologie Intégrée Nantes Angers, INSERM UMR 1307, CNRS UMR 6075, Nantes, France; Site de Recherche Intégrée sur le Cancer (SIRIC), Imaging and Longitudinal Investigations to Ameliorate Decision-Making (ILIAD), INCA-DGOS-Inserm 12558, Nantes, France Immunology Laboratory, CIMNA, Nantes
| | | | - Antoine Bénichou
- Department of Internal and Vascular Medicine, University hospital, Nantes
| | - Cyrille Touzeau
- Department of hematology, University hospital, Nantes, France; Centre de Recherche en Cancérologie et Immunologie Intégrée Nantes Angers, INSERM UMR 1307, CNRS UMR 6075, Nantes, France; Site de Recherche Intégrée sur le Cancer (SIRIC), Imaging and Longitudinal Investigations to Ameliorate Decision-Making (ILIAD), INCA-DGOS-Inserm 12558, Nantes, France Immunology Laboratory, CIMNA, Nantes
| | - Benoît Tessoulin
- Department of hematology, University hospital, Nantes, France; Centre de Recherche en Cancérologie et Immunologie Intégrée Nantes Angers, INSERM UMR 1307, CNRS UMR 6075, Nantes.
| |
Collapse
|
6
|
Kevork K, Gouin M, Letailleur V, Chevallier P, Touzeau C, Gastinne T, Piron B, Tessoulin B. Failure to bispecific-antibody therapy is associated with a short survival in highly pre-treated patients with aggressive B-Cell Lymphomas. Curr Res Transl Med 2023; 71:103388. [PMID: 37099834 DOI: 10.1016/j.retram.2023.103388] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/09/2023] [Revised: 03/20/2023] [Accepted: 03/22/2023] [Indexed: 03/29/2023]
Affiliation(s)
- Kohar Kevork
- Nantes University Hospital, CRCI2NA, 1 Place Alexis Ricordeau, Nantes 44093, France
| | - Melanie Gouin
- Nantes University Hospital, CRCI2NA, 1 Place Alexis Ricordeau, Nantes 44093, France
| | - Valentin Letailleur
- Nantes University Hospital, CRCI2NA, 1 Place Alexis Ricordeau, Nantes 44093, France
| | - Patrice Chevallier
- Nantes University Hospital, CRCI2NA, 1 Place Alexis Ricordeau, Nantes 44093, France
| | - Cyrille Touzeau
- Nantes University Hospital, CRCI2NA, 1 Place Alexis Ricordeau, Nantes 44093, France
| | - Thomas Gastinne
- Nantes University Hospital, CRCI2NA, 1 Place Alexis Ricordeau, Nantes 44093, France
| | - Bénédicte Piron
- Nantes University Hospital, CRCI2NA, 1 Place Alexis Ricordeau, Nantes 44093, France
| | - Benoît Tessoulin
- Nantes University Hospital, CRCI2NA, 1 Place Alexis Ricordeau, Nantes 44093, France.
| |
Collapse
|
7
|
Le Calvez B, Eveillard M, Decamps P, Aguilar J, Seguin A, Canet E, Grain A, Touzeau C, Tessoulin B, Gastinne T. Extensive myelitis with eosinophilic meningitis after Chimeric antigen receptor T cells therapy. eJHaem 2022; 3:533-536. [PMID: 35846023 PMCID: PMC9175988 DOI: 10.1002/jha2.381] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 12/02/2021] [Revised: 01/04/2022] [Accepted: 01/06/2022] [Indexed: 11/26/2022]
Abstract
Immune effector cell‐associated neurotoxicity syndrome (ICANS) is a frequent adverse event after Chimeric antigen receptor T cells (CAR‐T cells). A patient treated with anti‐CD19 CAR‐T cells for a refractory mantle cell lymphoma presented at Day 8 post‐infusion with extensive myelitis. Unusual eosinophilia was disclosed in the patient's cerebrospinal fluid. After treatment with methylprednisolone and siltuximab, a decrease in clinical symptoms and magnetic resonance imaging lesions were obtained. This unprecedented presentation of eosinophilic meningitis after CAR‐T cells therapy highlights the need for a better understanding of the physiopathology of ICANS, especially to identify potentially targetable pathways.
Collapse
Affiliation(s)
- Baptiste Le Calvez
- Department of Hematology Nantes University hospital Nantes France
- Pediatric Oncology Nantes University Hospital Nantes France
| | - Marion Eveillard
- Nantes Université, INSERM, CNRS, Université d'Angers, CRCI2NA Nantes France
- Hematology Biology Nantes University Hospital Nantes France
| | - Paul Decamps
- Intensive Care Unit Nantes University Hospital Nantes France
| | - Jesus Aguilar
- Medical Imaging Unit Nantes University Hospital Nantes France
| | - Amélie Seguin
- Intensive Care Unit Nantes University Hospital Nantes France
| | - Emmanuel Canet
- Intensive Care Unit Nantes University Hospital Nantes France
| | - Audrey Grain
- Nantes Université, INSERM, CNRS, Université d'Angers, CRCI2NA Nantes France
- Pediatric Oncology Nantes University Hospital Nantes France
| | - Cyrille Touzeau
- Department of Hematology Nantes University hospital Nantes France
- Nantes Université, INSERM, CNRS, Université d'Angers, CRCI2NA Nantes France
- Site de Recherche Intégrée sur le Cancer, ILIAD INCA‐DGOS‐Inserm U12558 Nantes France
| | - Benoît Tessoulin
- Department of Hematology Nantes University hospital Nantes France
- Nantes Université, INSERM, CNRS, Université d'Angers, CRCI2NA Nantes France
- Site de Recherche Intégrée sur le Cancer, ILIAD INCA‐DGOS‐Inserm U12558 Nantes France
| | - Thomas Gastinne
- Department of Hematology Nantes University hospital Nantes France
| |
Collapse
|
8
|
Le Scornet T, Martin F, Dejoie T, Caristan A, Tessoulin B, Agard C, Touzeau C, Hamidou M, Ville S, Néel A. Facteurs pronostiques des cryoglobulinémies à composante monoclonale primitives. Rev Med Interne 2021. [DOI: 10.1016/j.revmed.2021.10.227] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
9
|
Le Bourgeois A, Coste-Burel M, Guillaume T, Peterlin P, Garnier A, Imbert BM, Drumel T, Mahé B, Dubruille V, Blin N, Lok A, Touzeau C, Gastinne T, Tessoulin B, Jullien M, Vantyghem S, Moreau P, Le Gouill S, Béné MC, Chevallier P. Interest of a third dose of BNT162b2 anti-SARS-CoV-2 messenger RNA vaccine after allotransplant. Br J Haematol 2021; 196:e38-e40. [PMID: 34671982 PMCID: PMC8653164 DOI: 10.1111/bjh.17911] [Citation(s) in RCA: 12] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/02/2021] [Revised: 10/05/2021] [Accepted: 10/08/2021] [Indexed: 01/11/2023]
Affiliation(s)
| | | | | | - Pierre Peterlin
- Hematology Department, Nantes University Hospital, Nantes, France
| | - Alice Garnier
- Hematology Department, Nantes University Hospital, Nantes, France
| | | | - Thomas Drumel
- Virology Department, Nantes University Hospital, Nantes, France
| | - Beatrice Mahé
- Hematology Department, Nantes University Hospital, Nantes, France
| | | | - Nicolas Blin
- Hematology Department, Nantes University Hospital, Nantes, France
| | - Anne Lok
- Hematology Department, Nantes University Hospital, Nantes, France
| | - Cyrille Touzeau
- Hematology Department, Nantes University Hospital, Nantes, France
| | - Thomas Gastinne
- Hematology Department, Nantes University Hospital, Nantes, France
| | - Benoît Tessoulin
- Hematology Department, Nantes University Hospital, Nantes, France
| | - Maxime Jullien
- Hematology Department, Nantes University Hospital, Nantes, France
| | - Sophie Vantyghem
- Hematology Department, Nantes University Hospital, Nantes, France
| | - Philippe Moreau
- Hematology Department, Nantes University Hospital, Nantes, France
| | - Steven Le Gouill
- Hematology Department, Nantes University Hospital, Nantes, France
| | - Marie C Béné
- INSERM UMR1232, CRCINA IRS-UN, Nantes University, Nantes, France.,Hematology Biology, Nantes University Hospital, Nantes, France
| | - Patrice Chevallier
- Hematology Department, Nantes University Hospital, Nantes, France.,INSERM UMR1232, CRCINA IRS-UN, Nantes University, Nantes, France
| |
Collapse
|
10
|
Wahbi A, Tessoulin B, Bretonnière C, Boileau J, Carpentier D, Decaux O, Fardet L, Geri G, Godmer P, Goujard C, Maisonneuve H, Mari A, Pouchot J, Ziza JM, Georgin-Lavialle S, Hamidou M, Néel A. Catastrophic adult-onset Still's disease as a distinct life-threatening clinical subset: case-control study with dimension reduction analysis. Arthritis Res Ther 2021; 23:256. [PMID: 34635157 PMCID: PMC8504015 DOI: 10.1186/s13075-021-02631-7] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/08/2021] [Accepted: 09/16/2021] [Indexed: 11/21/2022] Open
Abstract
Objectives Adult-onset Still’s disease (AOSD) is a rare systemic inflammatory disorder. Diagnosing AOSD can be challenging, as disease presentation and clinical course are highly heterogeneous. For unclear reasons, a few patients develop life-threatening complications. Our objective was to determine whether these cases resulted from therapeutic delay or could represent a peculiar AOSD subset. Methods We conducted a multicentre retrospective study of 20 AOSD patients with organ failure requiring intensive care unit admission and 41 control AOSD patients without organ failure. Clinico-biological data at hospital admission were explored using supervised analyses and unsupervised dimension reduction analysis (factor analysis of mixed data, FAMD). Results Disease duration before admission was shorter in patients with life-threatening AOSD (median, 10 vs 20 days, p = 0.007). Disease duration before AOSD therapy initiation also tended to be shorter (median, 24 vs 32 days, p = 0.068). Despite this shorter disease duration, FAMD, hierarchical clustering and univariate analyses showed that these patients exhibited distinctive characteristics at first presentation, including younger age; higher frequency of splenomegaly, liver, cardiac and/or lung involvement; less frequent arthralgia; and higher ferritin level. In multivariate analysis, 3 parameters predicted life-threatening complications: lack of arthralgia, younger age and shorter time between fever onset and hospitalisation. Conclusion This study suggests that life-threatening complications of AOSD occur very early, in a peculiar subset, which we propose to name catastrophic adult-onset Still’s disease (CAOSD). Its exact burden may be underestimated and remains to be clarified through large multicentre cohorts. Further studies are needed to identify red flags and define the optimal therapeutic strategy.
Collapse
Affiliation(s)
- Anaïs Wahbi
- Service de Médecine Interne, PHU3, Centre Hospitalier Universitaire de Nantes - Hôtel-Dieu, 1 Place Alexis Ricordeau, 44093, Nantes, France
| | - Benoît Tessoulin
- Service d'Hématologie, PHU1, CHU Hôtel-Dieu, 44093, Nantes, France
| | - Cédric Bretonnière
- Service de Pneumologie, PHU2, CHU de Nantes, 44093, Nantes, France.,UPRES EA 3826, Faculté de Médecine, Université de Nantes, 44035, Nantes, France
| | - Julien Boileau
- Service de Médecine, CH de Morlaix, 29672, Morlaix, France
| | | | - Olivier Decaux
- Service de Médecine Interne, CHU de Rennes, 35033, Rennes, France
| | - Laurence Fardet
- Service de Dermatologie, Hôpital Henri Mondor, 94000, Créteil, France
| | - Guillaume Geri
- Service de Réanimation Médicale, CHU Cochin, AP-HP, 75012, Paris, France
| | | | - Cécile Goujard
- Service de Médecine Interne, CHU Bicêtre, AP-HP, 94270, Kremlin-Bicêtre, France
| | - Hervé Maisonneuve
- Service de Médecine Interne, CHD Vendée, 85925, La Roche-sur-Yon, France
| | - Arnaud Mari
- Service de Réanimation, Hôpital Yves Le Foll, 22000, St Brieuc, France
| | - Jacques Pouchot
- Service de Médecine Interne, Hôpital Européen Georges Pompidou, AP-HP, 75908, Paris, France
| | - Jean-Marc Ziza
- Service de Médecine Interne-Rhumatologie, Groupe Hospitalier Diaconesses-Croix-Saint-Simon, 75020, Paris, France
| | | | - Mohamed Hamidou
- Service de Médecine Interne, PHU3, Centre Hospitalier Universitaire de Nantes - Hôtel-Dieu, 1 Place Alexis Ricordeau, 44093, Nantes, France
| | - Antoine Néel
- Service de Médecine Interne, PHU3, Centre Hospitalier Universitaire de Nantes - Hôtel-Dieu, 1 Place Alexis Ricordeau, 44093, Nantes, France.
| |
Collapse
|
11
|
Lécuyer R, Issa N, Tessoulin B, Morio F, Gabriel F, Canet E, Boutoille D, Raffi F, Camou F, Gaborit B. Épidémiologie et impact pronostique des co-infections respiratoires associées au diagnostic de pneumocystose. Infect Dis Now 2021. [DOI: 10.1016/j.idnow.2021.06.023] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
12
|
Gastinne T, Bouabdallah K, Moatti H, Tessoulin B, Shiano del colella JM, Lamy T, Casasnovas O, Borel C, Stamatoullas A, Gac AC, Chaoui D, Feugier P, Delmer A, Bonnet C, Fornecker L, Lazarovici J, Bras F, Ghesquieres H, Meignan M, Traverse Glehen A, Brice P. BRENTUXIMAB VEDOTIN AS CONSOLIDATION TREATMENT IN PATIENTS WITH STAGE I/II CLASSICAL HODGKIN'S LYMPHOMA AND A POSITIVE FDG‐PET AFTER 2 CYCLES OF ABVD: A LYSA PHASE 2 STUDY. Hematol Oncol 2021. [DOI: 10.1002/hon.111_2880] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Affiliation(s)
- T. Gastinne
- University Hospital of Nantes Hematology Nantes France
| | - K. Bouabdallah
- Hopital Haut‐Levêque Centre Hospitalier Regional Universitaire de Bordeaux Department of Hematology Pessac France
| | - H. Moatti
- Hôpital saint Louis APHP Université Paris 7 Department of Oncohaematology Paris France
| | - B. Tessoulin
- University Hospital of Nantes Hematology Nantes France
| | | | - T. Lamy
- Rennes University Hospital Department of Clinical Hematology MICA Research Unit Rennes France
| | - O. Casasnovas
- University Hospital F Mitterrand and INSERM 1231 Department of Haematology Dijon France
| | - C. Borel
- IUCT‐Oncopole CHU Toulouse Department of Haematology Toulouse France
| | - A. Stamatoullas
- Centre Henri Becquerel Department of Haematology U918 Rouen France
| | - A. C. Gac
- Centre Hospitalier Universitaire de Caen Institut d'hématologie de Basse‐Normandie Caen France
| | - D. Chaoui
- Centre Hospitalier d'Argenteuil Department of Hematology Argenteuil France
| | - P. Feugier
- Nancy University Hospital Department of Clinical Hematology INSERM 1256 Nancy France
| | - A. Delmer
- University Hospital of Reims Department of Haematology Reims France
| | - C. Bonnet
- CHU Liège, Liège Université Campus Universitaire de Sart Tilman Clinical Hematology Unit Liège Belgium
| | - Luc‐M. Fornecker
- Strasbourg University Hospital Department of Clinical Hematology Strasbourg France
| | - J. Lazarovici
- Institut Gustave Roussy Département des Innovations Thérapeutiques et Essais Précoces Villejuif France
| | - F. Bras
- CHU Henri Mondor Department of Hematology Creteil France
| | - H. Ghesquieres
- Hospices Civils de Lyon Centre Hospitalier Lyon‐Sud and Université Claude Bernard Lyon‐1 Department of Haematology Lyon France
| | - M. Meignan
- Hôpital H Mondor LYSA Imaging Creteil France
| | - A. Traverse Glehen
- Centre Hospitalier Lyon‐Sud Hospices Civils de Lyon Pathology Department cedex, France, Lyon France
| | - P. Brice
- Hôpital saint Louis APHP Université Paris 7 Department of Oncohaematology Paris France
| |
Collapse
|
13
|
Chevallier P, Berceanu A, Peterlin P, Garnier A, Le Bourgeois A, Imbert BM, Daguindau E, Mahé B, Dubruille V, Blin N, Touzeau C, Gastinne T, Lok A, Tessoulin B, Vantyghem S, Desbrosses Y, Bressollette C, Duquesne A, Eveillard M, Le Bris Y, Dormoy A, Malugani C, Deconinck E, Moreau P, Le Gouill S, Béné MC, Guillaume T. Grade 2 acute GVHD is a factor of good prognosis in patients receiving peripheral blood stem cells haplo-transplant with post-transplant cyclophosphamide. Acta Oncol 2021; 60:466-474. [PMID: 33112687 DOI: 10.1080/0284186x.2020.1837947] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
Abstract
BACKGROUND The impact of acute graft versus host disease (GVHD) on survivals for patients receiving a haploidentical allogeneic stem-cell transplant (Allo-SCT) with peripheral blood stem-cells (PBSC) complemented by post-transplant cyclophosphamide (PTCY) is ill-known. MATERIAL AND METHODS This retrospective study included 131 patients who received a PBSC haplograft in order to precise the impact of acute GVHD on outcomes. There were 78 males and 53 females and the median age for the whole cohort was 59 years (range: 20-71). Thirty-five patients were allografted for a lymphoid disease and 96 for a myeloid malignancy, including 67 patients with acute myeloid leukemia (AML). RESULTS The cumulative incidence (CI) of day 100 grade 2-4 and 3-4 acute GVHD was 43.4 + 4.6% and 16.7 + 3.4%, respectively. The 2-year CI of moderate/severe chronic GVHD was 10.1 + 2.8%. The only factor affecting the occurrence of GVHD was GVHD prophylaxis. Indeed, CI of day 100 grade 2-4 (but not grade 3-4) acute GVHD was significantly reduced when adding anti-thymoglobulin (ATG) to PTCY. However, in multivariate analysis, grade 2 acute GVHD was significantly associated with better disease-free (HR: 0.36; 95%CI: 0.19-0.69, p = .002) and overall (HR: 0.35; 95%CI: 0.1-0.70, p = .003) survivals. The same results were observed when considering only AML patients. CONCLUSION Acute grade 2 GVHD is a factor of good prognosis after PBSC haplotransplant with PTCY. Further and larger studies are needed to clarify the complex question of GVHD prophylaxis in the setting of haplo-transplant, especially that of combining ATG and PTCY.
Collapse
Affiliation(s)
| | | | | | - Alice Garnier
- Hematology Department, CHU Hotel-Dieu, Nantes, France
| | | | | | | | - Béatrice Mahé
- Hematology Department, CHU Hotel-Dieu, Nantes, France
| | | | - Nicolas Blin
- Hematology Department, CHU Hotel-Dieu, Nantes, France
| | | | | | - Anne Lok
- Hematology Department, CHU Hotel-Dieu, Nantes, France
| | | | | | | | | | - Alix Duquesne
- Cellular Engineering Unit, EFS Pays de la Loire, Nantes, France
| | | | - Yannick Le Bris
- Hematology/Biology Department, CHU Hotel-Dieu, Nantes, France
| | - Anne Dormoy
- EFS Bourgogne Franche-Comté, Besançon, France
| | | | - Eric Deconinck
- Hematology Department, CHU, Besançon, France
- Université de Franche-Comté, Inserm UMR1098 RIGHT, Besançon, France
| | | | | | - Marie C. Béné
- Hematology/Biology Department, CHU Hotel-Dieu, Nantes, France
| | | |
Collapse
|
14
|
Peterlin P, Gaschet J, Guillaume T, Garnier A, Eveillard M, Le Bourgeois A, Cherel M, Debord C, Le Bris Y, Theisen O, Godon C, Mahé B, Dubruille V, Wuilleme S, Touzeau C, Gastinne T, Blin N, Lok A, Tessoulin B, Le Gouill S, Moreau P, Béné MC, Chevallier P. A new cytokine-based dynamic stratification during induction is highly predictive of survivals in acute myeloid leukemia. Cancer Med 2020; 10:642-648. [PMID: 33369136 PMCID: PMC7877358 DOI: 10.1002/cam4.3648] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/17/2020] [Revised: 10/29/2020] [Accepted: 11/19/2020] [Indexed: 11/28/2022] Open
Abstract
The aim of this study was to assess the potential impact of the kinetics of serum levels of seven cytokines during induction in acute myeloid leukemia (AML) patients. Indeed, the role of cytokines, in the pathophysiology and response to therapy of AML patients, remains under investigation. Here, we report on the impact of peripheral levels of two cytokines, the Fms‐like tyrosine kinase 3 ligand (FL) and interleukin‐6 (IL‐6), evaluated during first‐line intensive induction. A new risk stratification can be proposed, which supersedes the ELN 2017 classification to predict survivals in AML patients by examining the kinetic profile of these cytokines during the induction phase. It segregates three groups of, respectively, high‐risk, characterized by a stagnation of low FL levels, intermediate risk, with dynamic increasing FL levels and high IL‐6 at day 22, and favorable risk with increasing FL levels but low IL‐6 at day 22.
Collapse
Affiliation(s)
- Pierre Peterlin
- Hematology Clinic, CHU, Nantes, France.,CRCINA, INSERM, Université d'Angers, Université de Nantes, Nantes, France
| | - Joelle Gaschet
- CRCINA, INSERM, Université d'Angers, Université de Nantes, Nantes, France
| | - Thierry Guillaume
- Hematology Clinic, CHU, Nantes, France.,CRCINA, INSERM, Université d'Angers, Université de Nantes, Nantes, France
| | | | - Marion Eveillard
- CRCINA, INSERM, Université d'Angers, Université de Nantes, Nantes, France.,Hematology Biology, CHU, Nantes, France
| | | | - Michel Cherel
- CRCINA, INSERM, Université d'Angers, Université de Nantes, Nantes, France.,Nuclear Medicine Unit, ICO Cancer Center Gauducheau, Saint Herblain, France
| | | | - Yannick Le Bris
- CRCINA, INSERM, Université d'Angers, Université de Nantes, Nantes, France.,Hematology Biology, CHU, Nantes, France
| | | | | | | | | | | | | | | | | | - Anne Lok
- Hematology Clinic, CHU, Nantes, France
| | | | - Steven Le Gouill
- Hematology Clinic, CHU, Nantes, France.,CRCINA, INSERM, Université d'Angers, Université de Nantes, Nantes, France
| | - Philippe Moreau
- Hematology Clinic, CHU, Nantes, France.,CRCINA, INSERM, Université d'Angers, Université de Nantes, Nantes, France
| | - Marie-C Béné
- CRCINA, INSERM, Université d'Angers, Université de Nantes, Nantes, France.,Hematology Biology, CHU, Nantes, France
| | - Patrice Chevallier
- Hematology Clinic, CHU, Nantes, France.,CRCINA, INSERM, Université d'Angers, Université de Nantes, Nantes, France
| |
Collapse
|
15
|
Belin C, Devic P, Ayrignac X, Dos Santos A, Paix A, Sirven-Villaros L, Simard C, Lamure S, Gastinne T, Ursu R, Berger C, Platon L, Tessoulin B, Azoulay E, Wallet F, Thieblemont C, Bachy E, Cartron G, Laplaud DA, Carpentier AF. Description of neurotoxicity in a series of patients treated with CAR T-cell therapy. Sci Rep 2020; 10:18997. [PMID: 33149178 PMCID: PMC7642402 DOI: 10.1038/s41598-020-76055-9] [Citation(s) in RCA: 50] [Impact Index Per Article: 12.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/10/2020] [Accepted: 10/20/2020] [Indexed: 12/25/2022] Open
Abstract
Chimeric antigen receptor-modified T (CAR T) cell therapy is a highly promising treatment for haematological malignancies but is frequently associated with cytokine release syndrome and neurotoxicity. Between July 2018 and July 2019, all patients treated with CD19-targeted CAR T-cell therapy for relapsing lymphoma were followed-up longitudinally to describe neurological symptoms and their evolution over time. Four different French centres participated and 84 patients (median age 59 years, 31% females) were included. Neurotoxicity, defined as the presence of at least one neurological symptom appearing after treatment infusion, was reported in 43% of the patients. The median time to onset was 7 days after infusion with a median duration of 6 days. More than half of the patients (64%) had grade 1–2 severity and 34% had grade 3–4. CRS was observed in 80% of all patients. The most frequent neurological symptoms were cognitive signs, being severe in 36%, and were equally distributed between language disorders and cognitive disorders without language impairment. Non-pyramidal motor disorders, severe in 11%, were reported in 42% of the patients. Elevation of C-reactive protein (CRP) within 4 days after treatment was significantly correlated with the occurrence of grade 3–4 neurotoxicity. Although sometimes severe, neurotoxicity was almost always reversible. The efficacy of steroids and antiepileptic drugs remains unproven in the management of neurotoxicity. Neurotoxicity associated with CAR T-cell therapies occurs in more than 40% of patients. The clinical pattern is heterogeneous but cognitive disorders (not limited to language disorders) and, to a minor degree, non-pyramidal motor disorders, appeared as a signature of severe neurotoxicity.
Collapse
Affiliation(s)
- Catherine Belin
- Department of Neurology, Hôpital Saint-Louis, Assistance Publique - Hôpitaux de Paris, 1 Avenue Claude Vellefaux, 75010, Paris, France.
| | - Perrine Devic
- Department of Clinical and Functional Neurology, Hospices Civils de Lyon, CHU Lyon Sud, 165 Chemin du Grand Revoyet, 69495, Pierre-Bénite, France
| | - Xavier Ayrignac
- Department of Neurology, Centre Hospitalier Universitaire de Montpellier, INSERM, 80 Avenue Augustin Fliche, 34295, Montpellier, France
| | - Amélie Dos Santos
- Department of Neurology, CRTI-InsermU1064, CIC 1413, Centre Hospitalier Universitaire de Nantes, 5 Allée de l'île Gloriette, 44093, Nantes, France
| | - Adrien Paix
- Institut de Radiothérapie de Bobigny, Ramsay Générale de Santé, Rue Lautréamont, 93000, Bobigny, France
| | - Lila Sirven-Villaros
- Department of Neurology, Hôpital Saint-Louis, Assistance Publique - Hôpitaux de Paris, 1 Avenue Claude Vellefaux, 75010, Paris, France.,Université de Paris, Paris-Diderot, 75010, Paris, France
| | - Claire Simard
- Department of Clinical and Functional Neurology, Hospices Civils de Lyon, CHU Lyon Sud, 165 Chemin du Grand Revoyet, 69495, Pierre-Bénite, France
| | - Sylvain Lamure
- Department of Clinical Haematology, Centre Hospitalier Universitaire de Montpellier, 80 Avenue Augustin Fliche, 34295, Montpellier, France
| | - Thomas Gastinne
- Department of Clinical Haematology, Centre Hospitalier Universitaire de Nantes, 5 Allée de l'île gloriette, 44093, Nantes, France
| | - Renata Ursu
- Department of Neurology, Hôpital Saint-Louis, Assistance Publique - Hôpitaux de Paris, 1 Avenue Claude Vellefaux, 75010, Paris, France
| | - Colette Berger
- Department of Clinical and Functional Neurology, Hospices Civils de Lyon, CHU Lyon Sud, 165 Chemin du Grand Revoyet, 69495, Pierre-Bénite, France
| | - Laura Platon
- Intensive Care Medicine Department, Lapeyronie Hospital, Centre Hospitalier Universitaire de Montpellier, 80 Avenue Augustin Fliche, 34295, Montpellier, France
| | - Benoît Tessoulin
- Department of Clinical Haematology, Centre Hospitalier Universitaire de Nantes, 5 Allée de l'île gloriette, 44093, Nantes, France
| | - Elie Azoulay
- Université de Paris, Paris-Diderot, 75010, Paris, France.,Intensive Care Medicine Department, Hôpital Saint-Louis, Assistance Publique-Hôpitaux de Paris, 75010, Paris, France
| | - Florent Wallet
- Intensive Care Medicine Department, Hospices Civils de Lyon, CHU Lyon Sud, 165 Chemin du Grand Revoyet, 69495, Pierre-Bénite, France
| | - Catherine Thieblemont
- Université de Paris, Paris-Diderot, 75010, Paris, France.,Department of Haemato-Oncology, Hôpital Saint-Louis, Assistance Publique-Hôpitaux de Paris, 75010, Paris, France
| | - Emmanuel Bachy
- Department of Clinical Haematology, Hospices Civils de Lyon, CHU Lyon Sud, 165 Chemin du Grand Revoyet, 69495, Pierre-Bénite, France.,INSERM U1052 CNRS, UMR5286, Centre de Recherche en Cancérologie de Lyon &, Université Claude Bernard, Lyon 1, France
| | - Guillaume Cartron
- Department of Clinical Haematology, Centre Hospitalier Universitaire de Montpellier, 80 Avenue Augustin Fliche, 34295, Montpellier, France
| | - David A Laplaud
- Department of Neurology, CRTI-InsermU1064, CIC 1413, Centre Hospitalier Universitaire de Nantes, 5 Allée de l'île Gloriette, 44093, Nantes, France
| | - Antoine F Carpentier
- Department of Neurology, Hôpital Saint-Louis, Assistance Publique - Hôpitaux de Paris, 1 Avenue Claude Vellefaux, 75010, Paris, France.,Université de Paris, Paris-Diderot, 75010, Paris, France
| |
Collapse
|
16
|
Le Bris Y, Magrangeas F, Moreau A, Chiron D, Guérin-Charbonnel C, Theisen O, Pichon O, Canioni D, Burroni B, Maisonneuve H, Thieblemont C, Oberic L, Gyan E, Pellat-Deceunynck C, Hermine O, Delfau-Larue MH, Tessoulin B, Béné MC, Minvielle S, Le Gouill S. Whole genome copy number analysis in search of new prognostic biomarkers in first line treatment of mantle cell lymphoma. A study by the LYSA group. Hematol Oncol 2020; 38:446-455. [PMID: 32472610 DOI: 10.1002/hon.2750] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/11/2020] [Revised: 05/11/2020] [Accepted: 05/24/2020] [Indexed: 11/09/2022]
Abstract
Mantle cell lymphoma (MCL) is a lymphoproliferative disorder characterized by the t(11;14)(q13;q32) CCND1/IGH translocation. This lymphoma is however extremely heterogeneous in terms of molecular alterations. Moreover, the course of the disease can vary greatly between indolent forms with slow progression and aggressive conditions rapidly pejorative. The identification of early markers allowing to predict individual patients outcome has however been unsuccessful so far. The LyMa trial treated homogeneously a cohort of young MCL patients. This appeared as a good opportunity to search for biomarkers of response to therapy. DNA extracted from diagnostic paraffin-embedded lymph node biopsies from 100 patients with newly diagnosed MCL, homogeneously treated in this prospective clinical trial, were investigated for copy number alterations and copy neutral loss of heterozygosity using the Oncoscan SNP-array scanning the whole genome. An independent confirmatory cohort was used to strengthen the possibly relevant anomalies observed. Here we describe the recurrent anomalies identified with this technique. Deletions of 17p(TP53) and 9p(CDKN2A) were more frequent in refractory or early relapsing patients (10%), but had no significant impact in univariate analysis on progression-free (PFS) or overall survival (OS). Regardless of the presence of TP53 or CDKN2A deletions, gains in 7p22 (8,5%) were associated with better PFS in univariate but not in multivariate analysis including MCL International Prognostic Index and treatment. Gains of 11q(CCDN1), suggesting gains of the CCND1/IGH fusion, were associated with worse OS and PFS in univariate and multivariate analyses. This worse prognosis impact was confirmed by FISH in an independent confirmatory cohort. This work, using a whole genome approach, confirms the broad genomic landscape of MCL and shows that gains of the CCND1/IGH fusion can be considered as a new prognostic structural variant. Genomic abnormalities of prognostic impact could be useful to strengthen or de-escalate treatment schedules or choosing targeted therapies or CART-cells.
Collapse
Affiliation(s)
- Yannick Le Bris
- Hematology Biology Department, Nantes University Hospital, Nantes, France.,CRCINA, INSERM, CNRS, Université d'Angers, Université de Nantes, Nantes, France
| | - Florence Magrangeas
- CRCINA, INSERM, CNRS, Université d'Angers, Université de Nantes, Nantes, France
| | - Anne Moreau
- Pathology Department Nantes University Hospital, now in Centre Hospitalier Départemental de Vendée, La Roche sur Yon, France
| | - David Chiron
- CRCINA, INSERM, CNRS, Université d'Angers, Université de Nantes, Nantes, France
| | - Catherine Guérin-Charbonnel
- CRCINA, INSERM, CNRS, Université d'Angers, Université de Nantes, Nantes, France.,Institut de Cancérologie de l'Ouest, U892, Saint-Herblain, France
| | - Olivier Theisen
- Hematology Biology Department, Nantes University Hospital, Nantes, France
| | - Olivier Pichon
- Genetic Department, Nantes University Hospital, Nantes, France
| | | | - Barbara Burroni
- Pathology Department, Cochin University Hospital, Paris, France
| | - Hervé Maisonneuve
- Hematology Clinic, Centre Hospitalier Départemental de Vendée, La Roche sur Yon, France
| | | | - Lucie Oberic
- Clinical Hematology Department, IUCT Oncopole, Toulouse University Hospital, Toulouse, France
| | - Emmanuel Gyan
- Clinical Hematology Department, Tours University Hospital, Tours, France
| | | | - Olivier Hermine
- Clinical Hematology Department, Necker University Hospital, Paris, France
| | | | - Benoît Tessoulin
- CRCINA, INSERM, CNRS, Université d'Angers, Université de Nantes, Nantes, France.,Clinical Hematology Department, Nantes University Hospital, Nantes, France
| | - Marie-Christine Béné
- Hematology Biology Department, Nantes University Hospital, Nantes, France.,CRCINA, INSERM, CNRS, Université d'Angers, Université de Nantes, Nantes, France
| | - Stéphane Minvielle
- CRCINA, INSERM, CNRS, Université d'Angers, Université de Nantes, Nantes, France
| | - Steven Le Gouill
- CRCINA, INSERM, CNRS, Université d'Angers, Université de Nantes, Nantes, France.,Clinical Hematology Department, Nantes University Hospital, Nantes, France
| |
Collapse
|
17
|
Ducloyer JB, Ducloyer M, Tessoulin B, Lebranchu P, Deltour JB. [Orbital myeloid sarcoma secondary to acute myeloblastic leukemia]. J Fr Ophtalmol 2019; 43:e15-e16. [PMID: 31813551 DOI: 10.1016/j.jfo.2019.06.018] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/14/2019] [Accepted: 06/25/2019] [Indexed: 11/25/2022]
Affiliation(s)
- J-B Ducloyer
- Service d'ophtalmologique, CHU de Nantes, 1, place Alexis-Ricordeau, 44093 Nantes cedex 01, France.
| | - M Ducloyer
- Service de radiologie, CHU de Nantes, 1, place Alexis-Ricordeau, 44093 Nantes cedex 01, France
| | - B Tessoulin
- Service d'hématologie clinique, CHU de Nantes, 1, place Alexis-Ricordeau, 44093 Nantes cedex 01, France
| | - P Lebranchu
- Service d'ophtalmologique, CHU de Nantes, 1, place Alexis-Ricordeau, 44093 Nantes cedex 01, France
| | - J-B Deltour
- Service d'ophtalmologique, CHU de Nantes, 1, place Alexis-Ricordeau, 44093 Nantes cedex 01, France
| |
Collapse
|
18
|
Thieblemont C, Le Gouill S, Di Blasi R, Cartron G, Morschhauser F, Bachy E, Paillassa J, Bernard S, Tessoulin B, Gastine T, Fegueux N, Kanouni T, Manier S, Sesques P, Houot R, Haouin C, Tilly H, Salles G. REAL-WORLD RESULTS ON CD19 CAR T-CELL FOR 60 FRENCH PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA INCLUDED IN A TEMPORARY AUTHORIZATION FOR USE PROGRAM. Hematol Oncol 2019. [DOI: 10.1002/hon.110_2630] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
Affiliation(s)
| | | | - R. Di Blasi
- Hematology; APHP; Saint-Louis Hospital Paris France
| | - G. Cartron
- Hematology; CHU Montpellier; Montpellier France
| | | | - E. Bachy
- Hematology; CHU Lyon; Pierre-Benite France
| | - J. Paillassa
- Hematology; APHP; Saint-Louis Hospital Paris France
| | - S. Bernard
- Hematology; APHP; Saint-Louis Hospital Paris France
| | | | | | - N. Fegueux
- Hematology; CHU Montpellier; Montpellier France
| | - T. Kanouni
- Hematology; CHU Montpellier; Montpellier France
| | - S. Manier
- Hematology; CHU Montpellier; Montpellier France
| | - P. Sesques
- Hematology; CHU Lyon; Pierre-Benite France
| | - R. Houot
- Hematology; CHU Rennes; Rennes France
| | - C. Haouin
- Hematology; APHP; Henri Mondor Hospital, Créteil France
| | - H. Tilly
- Hematology; Centre H. Becquerel; Rouen France
| | - G. Salles
- Hematology; CHU Lyon; Pierre-Benite France
| |
Collapse
|
19
|
Le Bris Y, Theisen O, Godon C, Tiab M, Moreau A, Bossard C, Subiger F, Chiron D, Gastinne T, Tessoulin B, Maisonneuve H, Le Gouill S, Béné M. INCREASED CCND1
FISH SIGNALS ARE ASSOCIATED WITH WORSE PROGNOSIS IN MANTLE CELL LYMPHOMA. Hematol Oncol 2019. [DOI: 10.1002/hon.4_2631] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
Affiliation(s)
- Y. Le Bris
- Hematology Biology; Nantes University Hospital; Nantes France
| | - O. Theisen
- Hematology Biology; Nantes University Hospital; Nantes France
| | - C. Godon
- Hematology Biology; Nantes University Hospital; Nantes France
| | - M. Tiab
- Hematology Clinic; Centre Hospitalier Départemental de Vendée; La Roche sur Yon France
| | - A. Moreau
- Pathology; Nantes University Hospital; Nantes France
| | - C. Bossard
- Pathology; Nantes University Hospital; Nantes France
| | - F. Subiger
- Biology; Centre Hospitalier Départemental de Vendée; La Roche sur Yon France
| | - D. Chiron
- INSERM_U1232, CRCINA, INSERM, CNRS; Université d'Angers, Université de Nantes; Nantes France
| | - T. Gastinne
- Hematology Clinic; Nantes University Hospital; Nantes France
| | - B. Tessoulin
- Hematology Clinic; Nantes University Hospital; Nantes France
| | - H. Maisonneuve
- Hematology Clinic; Centre Hospitalier Départemental de Vendée; La Roche sur Yon France
| | - S. Le Gouill
- Hematology Clinic; Nantes University Hospital; Nantes France
| | - M. Béné
- Hematology Biology; Nantes University Hospital; Nantes France
| |
Collapse
|
20
|
Ferrero S, Ladetto M, Beldjord K, Drandi D, Stelitano C, Bernard S, Castagnari B, Bouabdallah K, Cesaretti M, Alvarez I, Gressin R, Ponzoni M, Tripodo C, Traverse-Glehen A, Baseggio L, Liberati A, Merli M, Tessoulin B, Patti C, Cabras M, Feugier P, Pozzi S, Zucca E, Iannitto E, Thieblemont C. FIRST APPLICATION OF MINIMAL RESIDUAL DISEASE ANALYSIS IN SPLENIC MARGINAL ZONE LYMPHOMA TRIALS: PRELIMINARY RESULTS FROM BRISMA/IELSG36 PHASE II STUDY. Hematol Oncol 2019. [DOI: 10.1002/hon.39_2630] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Affiliation(s)
- S. Ferrero
- Hematology Division; Università di Torino, Molecular Biotechnologies and Health Sciences; Torino Italy
| | - M. Ladetto
- Azienda Ospedaliera Nazionale SS. Antonio e Biagio e Cesare Arrigo; SC Ematologia; Alessandria Italy
| | - K. Beldjord
- Hemato-Oncology; Hôpital Saint-Louis; Paris France
| | - D. Drandi
- Hematology Division; Università di Torino, Molecular Biotechnologies and Health Sciences; Torino Italy
| | - C. Stelitano
- U.O.C. Ematologia; Grande Ospedale Metropolitano Bianchi Melacrino Morelli; Reggio Calabria Italy
| | - S. Bernard
- Hemato-Oncology; Hôpital Saint-Louis; Paris France
| | - B. Castagnari
- UOC of Hematology; Hospital Santa Maria delle Croci; Ravenna Italy
| | | | - M. Cesaretti
- University of Modena and Reggio Emilia; Department of Diagnostic, Clinical and Public Health Medicine; Modena Italy
| | - I. Alvarez
- AUSL Reggio Emilia/IRCCS; Arcispedale Santa Maria Nuova, UOC of Hematology; Reggio Emilia Italy
| | - R. Gressin
- Grenoble Alpes University Hospital; Department of Hematology; Grenoble France
| | - M. Ponzoni
- Pathology Unit; Ateneo Vita-Salute and San Raffaele Scientific Institute; Milano Italy
| | - C. Tripodo
- Department of Health Science; Human Pathology Section,Tumor Immunology Unit, University of Palermo; Palermo Italy
| | | | - L. Baseggio
- Pierre-Benite; Cytology, CHU Lyon; Lyon France
| | - A. Liberati
- University of Perugia; Oncology-Hematology, Santa Maria Hospital; Terni Italy
| | - M. Merli
- ASST Settelaghi; University Hospital Ospedale di Circolo e Fondazione Macchi; Varese Italy
| | | | - C. Patti
- Division of Hematology; Azienda Ospedali Riuniti Villa Sofia-Cervello; Palermo Italy
| | - M. Cabras
- Ospedale Businco; Division of Hematology; Cagliari Italy
| | - P. Feugier
- University Hospital of Nancy; Department of Haematology; Nancy France
| | - S. Pozzi
- Unit of Target Therapy in Onco-Hematology and Osteoncology, University of Modena and Reggio Emilia, Department of Oncology and Hematology; Modena Cancer Center; Modena Italy
| | - E. Zucca
- Institute of Oncology Research; Università della Svizzera Italiana (USI), IOSI, Oncology Institute of Southern Switzerland and IOR; Bellinzona Switzerland
| | - E. Iannitto
- Department of Oncology; “La Maddalena”, Onco-Hematology and BMT Unit; Palermo Italy
| | | |
Collapse
|
21
|
Gaborit B, Tessoulin B, Moriot F, Lavergne R, Bretonnière C, Lecomte R, Deschanvres C, Raffi F, Boutoille D, Reignier J. Analyse des facteurs pronostiques précoces de sévérité et mortalité au cours de la pneumocystose : étude observationnelle prospective sur 5 ans. Med Mal Infect 2019. [DOI: 10.1016/j.medmal.2019.04.184] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
22
|
Trudel S, Tessoulin B, Jullien M, Blin N, Gastinne T, Mahé B, Dubruille V, Bonnet A, Lok A, Chevallier P, Peterlin P, Garnier A, Guillaume T, Le Bourgeois A, Le Gouill S, Moreau P, Touzeau C. Pomalidomide, cyclophosphamide, and dexamethasone for relapsed/refractory multiple myeloma patients in a real-life setting: a single-center retrospective study. Ann Hematol 2019; 98:1441-1447. [PMID: 30874851 DOI: 10.1007/s00277-019-03649-3] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/08/2019] [Accepted: 02/27/2019] [Indexed: 10/27/2022]
Abstract
Pomalidomide dexamethasone is a standard of care for relapsed multiple myeloma (MM) patients who received at least two prior lines of therapy, including both lenalidomide and proteasome inhibitors (PI). We report here a real-life single-center series of 49 consecutive patients with relapsed and refractory MM treated with the triplet pomalidomide cyclophosphamide dexamethasone (PCD) combination. The median of prior lines of therapy was 3 and all patients were previously exposed to proteasome inhibitors and lenalidomide. The overall response rate was 76%, including 27% very good partial response or better. With a median follow-up of 16 months, the median progression-free survival (PFS) was 7.3 months and the median overall survival was not reached. Regarding safety, most frequent toxicity was hematologic, including 37% grade 3-4 cytopenias. Nine patients (18%) discontinued therapy due to adverse event. Our study confirms that PCD combination is feasible and results in favorable response rate and PFS in comparison with pomalidomide dexamethasone alone.
Collapse
Affiliation(s)
- Sabrina Trudel
- Department of Hematology, Centre Hospitalier Universitaire, Nantes, France
| | - Benoît Tessoulin
- Department of Hematology, Centre Hospitalier Universitaire, Nantes, France.,CRCINA, INSERM, CNRS, Université d'Angers, Université de Nantes, Nantes, France
| | - Maxime Jullien
- Department of Hematology, Centre Hospitalier Universitaire, Nantes, France
| | - Nicolas Blin
- Department of Hematology, Centre Hospitalier Universitaire, Nantes, France
| | - Thomas Gastinne
- Department of Hematology, Centre Hospitalier Universitaire, Nantes, France
| | - Béatrice Mahé
- Department of Hematology, Centre Hospitalier Universitaire, Nantes, France
| | - Viviane Dubruille
- Department of Hematology, Centre Hospitalier Universitaire, Nantes, France
| | - Antoine Bonnet
- Department of Hematology, Centre Hospitalier Universitaire, Nantes, France
| | - Anne Lok
- Department of Hematology, Centre Hospitalier Universitaire, Nantes, France
| | - Patrice Chevallier
- Department of Hematology, Centre Hospitalier Universitaire, Nantes, France
| | - Pierre Peterlin
- Department of Hematology, Centre Hospitalier Universitaire, Nantes, France
| | - Alice Garnier
- Department of Hematology, Centre Hospitalier Universitaire, Nantes, France
| | - Thierry Guillaume
- Department of Hematology, Centre Hospitalier Universitaire, Nantes, France
| | | | - Steven Le Gouill
- Department of Hematology, Centre Hospitalier Universitaire, Nantes, France.,CRCINA, INSERM, CNRS, Université d'Angers, Université de Nantes, Nantes, France.,Site de Recherche Intégrée sur le Cancer (SIRIC) «ILIAD», Nantes, France
| | - Philippe Moreau
- Department of Hematology, Centre Hospitalier Universitaire, Nantes, France.,CRCINA, INSERM, CNRS, Université d'Angers, Université de Nantes, Nantes, France.,Site de Recherche Intégrée sur le Cancer (SIRIC) «ILIAD», Nantes, France
| | - Cyrille Touzeau
- Department of Hematology, Centre Hospitalier Universitaire, Nantes, France. .,CRCINA, INSERM, CNRS, Université d'Angers, Université de Nantes, Nantes, France. .,Site de Recherche Intégrée sur le Cancer (SIRIC) «ILIAD», Nantes, France. .,Service d'hématologie Clinique, Centre Hospitalier Universitaire, Place Alexis Ricordeau, 44093, Nantes, France.
| |
Collapse
|
23
|
Tessoulin B, Papin A, Gomez-Bougie P, Bellanger C, Amiot M, Pellat-Deceunynck C, Chiron D. BCL2-Family Dysregulation in B-Cell Malignancies: From Gene Expression Regulation to a Targeted Therapy Biomarker. Front Oncol 2019; 8:645. [PMID: 30666297 PMCID: PMC6330761 DOI: 10.3389/fonc.2018.00645] [Citation(s) in RCA: 35] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/09/2018] [Accepted: 12/10/2018] [Indexed: 12/11/2022] Open
Abstract
BCL2-family proteins have a central role in the mitochondrial apoptosis machinery and their expression is known to be deregulated in many cancer types. Effort in the development of small molecules that selectively target anti-apoptotic members of this family i.e., Bcl-2, Bcl-xL, Mcl-1 recently opened novel therapeutic opportunities. Among these apoptosis-inducing agents, BH3-mimetics (i.e., venetoclax) led to promising preclinical and clinical activity in B cell malignancies. However, several mechanisms of intrinsic or acquired resistance have been described ex vivo therefore predictive markers of response as well as mechanism-based combinations have to be designed. In the present study, we analyzed the expression of the BCL2-family genes across 10 mature B cell malignancies through computational normalization of 21 publicly available Affimetrix datasets gathering 1,219 patient samples. To better understand the deregulation of anti- and pro-apoptotic members of the BCL2-family in hematological disorders, we first compared gene expression profiles of malignant B cells to their relative normal control (naïve B cell to plasma cells, n = 37). We further assessed BCL2-family expression according to tissue localization i.e., peripheral blood, bone marrow, and lymph node, molecular subgroups or disease status i.e., indolent to aggressive. Across all cancer types, we showed that anti-apoptotic genes are upregulated while pro-apoptotic genes are downregulated when compared to normal counterpart cells. Of interest, our analysis highlighted that, independently of the nature of malignant B cells, the pro-apoptotic BH3-only BCL2L11 and PMAIP1 are deeply repressed in tumor niches, suggesting a central role of the microenvironment in their regulation. In addition, we showed selective modulations across molecular subgroups and showed that the BCL2-family expression profile was related to tumor aggressiveness. Finally, by integrating recent data on venetoclax-monotherapy clinical activity with the expression of BCL2-family members involved in the venetoclax response, we determined that the ratio (BCL2+BCL2L11+BAX)/BCL2L1 was the strongest predictor of venetoclax response for mature B cell malignancies in vivo.
Collapse
Affiliation(s)
- Benoît Tessoulin
- CRCINA, INSERM, CNRS, Université d'Angers, Université de Nantes Nantes, France.,L'Héma-NexT, i-Site NexT Nantes, France.,Department of Hematology, Centre Hospitalier Universitaire Nantes, France
| | - Antonin Papin
- CRCINA, INSERM, CNRS, Université d'Angers, Université de Nantes Nantes, France.,L'Héma-NexT, i-Site NexT Nantes, France.,CNRS GDR3697 Micronit Tours, France
| | - Patricia Gomez-Bougie
- CRCINA, INSERM, CNRS, Université d'Angers, Université de Nantes Nantes, France.,L'Héma-NexT, i-Site NexT Nantes, France.,CNRS GDR3697 Micronit Tours, France
| | - Celine Bellanger
- CRCINA, INSERM, CNRS, Université d'Angers, Université de Nantes Nantes, France.,L'Héma-NexT, i-Site NexT Nantes, France.,CNRS GDR3697 Micronit Tours, France
| | - Martine Amiot
- CRCINA, INSERM, CNRS, Université d'Angers, Université de Nantes Nantes, France.,L'Héma-NexT, i-Site NexT Nantes, France.,CNRS GDR3697 Micronit Tours, France
| | - Catherine Pellat-Deceunynck
- CRCINA, INSERM, CNRS, Université d'Angers, Université de Nantes Nantes, France.,L'Héma-NexT, i-Site NexT Nantes, France.,CNRS GDR3697 Micronit Tours, France
| | - David Chiron
- CRCINA, INSERM, CNRS, Université d'Angers, Université de Nantes Nantes, France.,L'Héma-NexT, i-Site NexT Nantes, France.,CNRS GDR3697 Micronit Tours, France
| |
Collapse
|
24
|
Tessoulin B, Moreau-Aubry A, Descamps G, Gomez-Bougie P, Maïga S, Gaignard A, Chiron D, Ménoret E, Le Gouill S, Moreau P, Amiot M, Pellat-Deceunynck C. Whole-exon sequencing of human myeloma cell lines shows mutations related to myeloma patients at relapse with major hits in the DNA regulation and repair pathways. J Hematol Oncol 2018; 11:137. [PMID: 30545397 PMCID: PMC6293660 DOI: 10.1186/s13045-018-0679-0] [Citation(s) in RCA: 31] [Impact Index Per Article: 5.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/12/2018] [Accepted: 11/20/2018] [Indexed: 12/28/2022] Open
Abstract
Background Human myeloma cell lines (HMCLs) are widely used for their representation of primary myeloma cells because they cover patient diversity, although not fully. Their genetic background is mostly undiscovered, and no comprehensive study has ever been conducted in order to reveal those details. Methods We performed whole-exon sequencing of 33 HMCLs, which were established over the last 50 years in 12 laboratories. Gene expression profiling and drug testing for the 33 HMCLs are also provided and correlated to exon-sequencing findings. Results Missense mutations were the most frequent hits in genes (92%). HMCLs harbored between 307 and 916 mutations per sample, with TP53 being the most mutated gene (67%). Recurrent bi-allelic losses were found in genes involved in cell cycle regulation (RB1, CDKN2C), the NFκB pathway (TRAF3, BIRC2), and the p53 pathway (TP53, CDKN2A). Frequency of mutations/deletions in HMCLs were either similar to that of patients (e.g., DIS3, PRDM1, KRAS) or highly increased (e.g., TP53, CDKN2C, NRAS, PRKD2). MAPK was the most altered pathway (82% of HMCLs), mainly by RAS mutants. Surprisingly, HMCLs displayed alterations in epigenetic (73%) and Fanconi anemia (54%) and few alterations in apoptotic machinery. We further identified mutually exclusive and associated mutations/deletions in genes involved in the MAPK and p53 pathways as well as in chromatin regulator/modifier genes. Finally, by combining the gene expression profile, gene mutation, gene deletion, and drug response, we demonstrated that several targeted drugs overcome or bypass some mutations. Conclusions With this work, we retrieved genomic alterations of HMCLs, highlighting that they display numerous and unprecedented abnormalities, especially in DNA regulation and repair pathways. Furthermore, we demonstrate that HMCLs are a reliable model for drug screening for refractory patients at diagnosis or at relapse. Electronic supplementary material The online version of this article (10.1186/s13045-018-0679-0) contains supplementary material, which is available to authorized users.
Collapse
Affiliation(s)
- Benoît Tessoulin
- CRCINA, INSERM, CNRS, Université d'Angers, Université de Nantes, Nantes, France. .,Service d'Hématologie Clinique, Unité d'Investigation Clinique, CHU, Nantes, France.
| | - Agnès Moreau-Aubry
- CRCINA, INSERM, CNRS, Université d'Angers, Université de Nantes, Nantes, France
| | - Géraldine Descamps
- CRCINA, INSERM, CNRS, Université d'Angers, Université de Nantes, Nantes, France
| | | | - Sophie Maïga
- CRCINA, INSERM, CNRS, Université d'Angers, Université de Nantes, Nantes, France
| | | | - David Chiron
- CRCINA, INSERM, CNRS, Université d'Angers, Université de Nantes, Nantes, France
| | | | - Steven Le Gouill
- CRCINA, INSERM, CNRS, Université d'Angers, Université de Nantes, Nantes, France.,Service d'Hématologie Clinique, Unité d'Investigation Clinique, CHU, Nantes, France
| | - Philippe Moreau
- CRCINA, INSERM, CNRS, Université d'Angers, Université de Nantes, Nantes, France.,Service d'Hématologie Clinique, Unité d'Investigation Clinique, CHU, Nantes, France
| | - Martine Amiot
- CRCINA, INSERM, CNRS, Université d'Angers, Université de Nantes, Nantes, France
| | | |
Collapse
|
25
|
Tessoulin B, Thomare P, Delande E, Moynard J, Gastinne T, Moreau A, Bossard C, Mahé B, Blin N, Dubruille V, Touzeau C, Boudreault JS, Perrin F, Lok A, Guillaume T, Garnier A, Peterlin P, Gallas P, Chevallier P, Moreau P, Le Gouill S. Carboplatin instead of cisplatin in combination with dexamethasone, high-dose cytarabine with or without rituximab (DHAC+/−R) is an effective treatment with low toxicity in Hodgkin’s and non-Hodgkin’s lymphomas. Ann Hematol 2017; 96:943-950. [DOI: 10.1007/s00277-017-2981-2] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/27/2016] [Accepted: 03/16/2017] [Indexed: 10/19/2022]
|
26
|
Tessoulin B, Eveillard M, Lok A, Chiron D, Moreau P, Amiot M, Moreau-Aubry A, Le Gouill S, Pellat-Deceunynck C. p53 dysregulation in B-cell malignancies: More than a single gene in the pathway to hell. Blood Rev 2017; 31:251-259. [PMID: 28284458 DOI: 10.1016/j.blre.2017.03.001] [Citation(s) in RCA: 34] [Impact Index Per Article: 4.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/31/2016] [Accepted: 03/02/2017] [Indexed: 12/31/2022]
Abstract
TP53 deletion or mutation is frequent in B-cell malignancies and is associated with a low response rate. We describe here the p53 landscape in B-cell malignancies, from B-Acute Lymphoblastic Leukemia to Plasma Cell Leukemia, by analyzing incidence of gain or loss of function of actors both upstream and within the p53 pathway, namely MYC, RAS, ARF, MDM2, ATM and TP53. Abnormalities are not equally distributed and their incidence is highly variable among malignancies. Deletion and mutation, usually associated, of ATM or TP53 are frequent in Diffuse Large B-Cell Lymphoma and Mantle Cell Lymphoma. MYC gain, absent in post-GC malignancies, is frequent in B-Prolymphocytic-Leukemia, Multiple Myeloma and Plasma Cell Leukemias. RAS mutations are rare except in MM and PCL. Multiple Factorial Analysis notes that MYC deregulation is closely related to TP53 status. Moreover, MYC gain, TP53 deletion and RAS mutations are inversely correlated with survival. Based on this landscape, we further propose targeted therapeutic approaches for the different B-cell malignancies.
Collapse
Affiliation(s)
- B Tessoulin
- CRCINA, INSERM, CNRS, Université de Nantes, Université d'Angers, Nantes, France; Department of Hematology, Nantes University Hospital, Nantes, France.
| | - M Eveillard
- CRCINA, INSERM, CNRS, Université de Nantes, Université d'Angers, Nantes, France; Hematology Biology Department, Nantes University Hospital, Nantes, France
| | - A Lok
- CRCINA, INSERM, CNRS, Université de Nantes, Université d'Angers, Nantes, France; Department of Hematology, Nantes University Hospital, Nantes, France
| | - D Chiron
- CRCINA, INSERM, CNRS, Université de Nantes, Université d'Angers, Nantes, France
| | - P Moreau
- CRCINA, INSERM, CNRS, Université de Nantes, Université d'Angers, Nantes, France; Department of Hematology, Nantes University Hospital, Nantes, France
| | - M Amiot
- CRCINA, INSERM, CNRS, Université de Nantes, Université d'Angers, Nantes, France
| | - A Moreau-Aubry
- CRCINA, INSERM, CNRS, Université de Nantes, Université d'Angers, Nantes, France
| | - S Le Gouill
- CRCINA, INSERM, CNRS, Université de Nantes, Université d'Angers, Nantes, France; Department of Hematology, Nantes University Hospital, Nantes, France
| | - C Pellat-Deceunynck
- CRCINA, INSERM, CNRS, Université de Nantes, Université d'Angers, Nantes, France.
| |
Collapse
|
27
|
Tessoulin B, Ceballos P, Chevallier P, Blaise D, Tournilhac O, Gauthier J, Maillard N, Tabrizi R, Choquet S, Carras S, Ifrah N, Guillerm G, Mohty M, Tilly H, Socie G, Cornillon J, Hermine O, Daguindau É, Bachy E, Girault S, Marchand T, Oberic L, Reman O, Leux C, Le Gouill S. Allogeneic stem cell transplantation for patients with mantle cell lymphoma who failed autologous stem cell transplantation: a national survey of the SFGM-TC. Bone Marrow Transplant 2016; 51:1184-90. [PMID: 27111043 DOI: 10.1038/bmt.2016.102] [Citation(s) in RCA: 28] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/11/2015] [Revised: 03/06/2016] [Accepted: 03/08/2016] [Indexed: 11/09/2022]
Abstract
Poly-chemotherapy plus rituximab followed by autologous stem cell transplantation (auto-SCT) is standard care for untreated young patients with mantle cell lymphoma (MCL). Despite this intensive treatment, transplant patients remain highly susceptible to relapse over time. The French SFGM-TC performed a national survey on reduced-intensity conditioning allogeneic stem cell transplantation (RIC-allo-SCT) for fit relapsed/refractory patients who failed after auto-SCT (n=106). Median times of relapse after auto-SCT, and from auto-SCT to RIC-allo-SCT were 28 months and 3.6 years, respectively. Sixty per cent of patients received at least three lines of treatment before RIC-allo-SCT. Conditioning regimens for RIC-allo-SCT were heterogeneous. Twenty patients experienced grade III/IV aGvHD, extensive cGvHD was reported in 28 cases. Median follow-up after RIC-allo-SCT was 45 months. Median PFS after RIC-allo-SCT was 30.1 months and median overall survival was 62 months. Treatment-related mortality (TRM) at 1 year and 3 years were estimated at 28% and 32%, respectively. A total of 52 patients died; major causes of death were related to toxicity (n=34) and MCL (n=11). Patients in good response before RIC-allo-SCT experienced a better PFS and OS. Our work highlights the need for new RIC-allo-SCT MCL-tailored approaches to reduce TRM, and early and late relapse.
Collapse
Affiliation(s)
- B Tessoulin
- Department of Hematology, University Hospital, Nantes, France.,INSERM team 10 UMR 892, CRCNA, Nantes, France
| | - P Ceballos
- Department of Hematology, University Hospital, Montpellier, France
| | - P Chevallier
- Department of Hematology, University Hospital, Nantes, France
| | - D Blaise
- Department of Hematology, Paoli Calmettes, Marseille, France
| | - O Tournilhac
- Department of Hematology, University Hospital, Clermont-Ferrand, France
| | - J Gauthier
- Department of Hematology, University Hospital, Lille, France
| | - N Maillard
- Department of Hematology, University Hospital, Poitiers, France
| | - R Tabrizi
- Department of Hematology, University Hospital, Bordeaux, France
| | - S Choquet
- Department of Hematology, Pitie Salpetriere, Paris, France
| | - S Carras
- Department of Hematology, University Hospital, Grenoble, France
| | - N Ifrah
- Department of Hematology, University Hospital, Angers, France
| | - G Guillerm
- Department of Hematology, University Hospital, Brest, France
| | - M Mohty
- Department of Hematology, University Hospital-Saint Antoine, Paris, France
| | - H Tilly
- Department of Hematology, Centre Henri-Becquerel, Rouen, France
| | - G Socie
- Department of Hematology, Saint Louis Hospital, Paris, France
| | - J Cornillon
- Department of Hematology, Institut de Cancerologie de la Loire, Saint Etienne, France
| | - O Hermine
- Department of Hematology, Necker Hospital, Paris, France
| | - É Daguindau
- Department of Hematology, University Hospital, Besancon, France
| | - E Bachy
- Department of Hematology, University hospital, Lyon, France
| | - S Girault
- Department of Hematology, University Hospital, Limoges, France
| | - T Marchand
- Department of Hematology, University Hospital, Rennes, France
| | - L Oberic
- University Cancer Institute, Toulouse, France
| | - O Reman
- Department of Hematology, University Hospital, Caen, France
| | - C Leux
- Department of Epidemiology, University Hospital of Nantes, Nantes, France
| | - S Le Gouill
- Department of Hematology, University Hospital, Nantes, France.,INSERM team 10 UMR 892, CRCNA, Nantes, France.,Centre d'Investigation Clinique en Cancérologie (CI2C), CHU de Nantes, Nantes, France
| |
Collapse
|
28
|
Lassalle A, Thomaré P, Fronteau C, Mahé B, Jubé C, Blin N, Voldoire M, Dubruille V, Tessoulin B, Touzeau C, Chauvin C, Loirat M, Lok A, Bourcier J, Lestang E, Mocquet R, Barbarot V, Moreau P. Home administration of bortezomib in multiple myeloma is cost-effective and is preferred by patients compared with hospital administration: results of a prospective single-center study. Ann Oncol 2016; 27:314-8. [DOI: 10.1093/annonc/mdv563] [Citation(s) in RCA: 30] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/06/2015] [Accepted: 11/02/2015] [Indexed: 11/14/2022] Open
|
29
|
Néel A, Bucchia M, Tessoulin B, Bressollette C, Degauque N, Agard C, Graveleau J, Godmer P, Garandeau C, Perrin F, Fakhouri F, Hamidou M. Le CMV sous tend l’expansion des TEMRA aux cours des VAA, sans influer sur la présentation ni sur l’évolution de la maladie. Rev Med Interne 2015. [DOI: 10.1016/j.revmed.2015.10.313] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
30
|
Tessoulin B, Delaunay J, Chevallier P, Loirat M, Ayari S, Peterlin P, Le Gouill S, Gastinne T, Moreau P, Mohty M, Guillaume T. Azacitidine salvage therapy for relapse of myeloid malignancies following allogeneic hematopoietic SCT. Bone Marrow Transplant 2014; 49:567-71. [DOI: 10.1038/bmt.2013.233] [Citation(s) in RCA: 50] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/26/2013] [Revised: 11/19/2013] [Accepted: 11/26/2013] [Indexed: 11/09/2022]
|
31
|
Tessoulin B, Beyne-RAuzy O, Guerci A, Gyan E, Hunault M, Ianotto J, Shanti A, Stamatoullas A, Dreyfus F, Fenaux P, Delaunay J. P-309 Low/intermerdiate-1 risk MDS treated with high-dose rHu-EPO: Hematological responses and impact on quality of life, a prospective GFM study. Leuk Res 2013. [DOI: 10.1016/s0145-2126(13)70356-4] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|